BioNTech SE

BATS-CHIXE:22UAD Stock Report

Market Cap: €21.6b

BioNTech Valuation

Is 22UAD undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 22UAD when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 22UAD's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 22UAD's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 22UAD?

Key metric: As 22UAD is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 22UAD. This is calculated by dividing 22UAD's market cap by their current revenue.
What is 22UAD's PS Ratio?
PS Ratio7.9x
Sales€2.75b
Market Cap€21.61b

Price to Sales Ratio vs Peers

How does 22UAD's PS Ratio compare to its peers?

The above table shows the PS ratio for 22UAD vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average4.7x
GNS Genus
1.9x3.9%UK£1.2b
OXB Oxford Biomedica
3x18.4%UK£293.0m
BVXP Bioventix
10.7xn/aUK£145.6m
HLN Haleon
3.2x4.2%UK£36.0b
22UAD BioNTech
7.9x5.8%€23.6b

Price-To-Sales vs Peers: 22UAD is expensive based on its Price-To-Sales Ratio (7.9x) compared to the peer average (4.7x).

Price to Sales Ratio vs Industry

How does 22UAD's PS Ratio compare vs other companies in the GB Biotechs Industry?

8 CompaniesPrice / SalesEstimated GrowthMarket Cap
GNS Genus
1.9x3.9%US$1.62b
OXB Oxford Biomedica
3x18.4%US$379.54m
TRX Tissue Regenix Group
1.2x15.1%US$39.21m
AREC Arecor Therapeutics
3.9x2.4%US$24.70m
No. of Companies8PS01632486480+
8 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 22UAD is expensive based on its Price-To-Sales Ratio (7.9x) compared to the European Biotechs industry average (7.4x).

Price to Sales Ratio vs Fair Ratio

What is 22UAD's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

22UAD PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio7.9x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate 22UAD's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 22UAD forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€94.35
€129.62
+37.4%
11.0%€158.19€101.50n/a20
Mar ’26n/a
€134.40
0%
11.8%€166.11€114.13n/a20
Feb ’26n/a
€133.84
0%
12.1%€167.08€114.13n/a20
Jan ’26n/a
€131.19
0%
10.9%€163.73€115.25n/a19
Dec ’25n/a
€129.48
0%
9.6%€163.73€115.56n/a18
Nov ’25n/a
€119.08
0%
17.1%€157.49€82.32n/a18
Oct ’25n/a
€111.46
0%
19.6%€153.73€76.42n/a18
Sep ’25n/a
€99.20
0%
20.4%€155.58€77.33n/a18
Aug ’25n/a
€103.43
0%
20.3%€158.55€83.53n/a18
Jul ’25n/a
€103.54
0%
20.2%€159.58€83.53n/a18
Jun ’25n/a
€103.10
0%
20.4%€158.71€83.26n/a18
May ’25n/a
€106.61
0%
20.7%€157.51€83.26n/a18
Apr ’25n/a
€108.69
0%
23.6%€173.24€83.26n/a18
Mar ’25n/a
€116.57
0%
22.5%€173.24€91.15n/a17
Feb ’25n/a
€117.42
0%
22.4%€173.24€91.15n/a16
Jan ’25n/a
€120.35
0%
21.0%€168.70€91.15n/a16
Dec ’24n/a
€123.84
0%
23.0%€182.92€91.15n/a17
Nov ’24n/a
€131.90
0%
23.1%€182.92€96.35n/a17
Oct ’24n/a
€138.26
0%
22.9%€186.14€93.84n/a16
Sep ’24n/a
€142.84
0%
26.1%€228.18€90.88n/a17
Aug ’24n/a
€147.17
0%
24.7%€228.18€98.93n/a17
Jul ’24n/a
€151.88
0%
23.1%€228.18€98.93n/a16
Jun ’24n/a
€149.76
0%
23.4%€228.18€98.93n/a17
May ’24n/a
€162.50
0%
23.7%€240.01€116.67n/a17
Apr ’24n/a
€169.58
0%
22.2%€240.01€120.58n/a16
Mar ’24n/a
€193.08
0%
23.4%€278.56€132.36n/a15
Analyst Price Target
Consensus Narrative from 20 Analysts
€135.81
Fair Value
30.5% undervalued intrinsic discount
20
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/03/11 08:07
End of Day Share Price 2025/03/11 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

BioNTech SE is covered by 30 analysts. 18 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ishan MajumdarBaptista Research
Zhiqiang ShuBerenberg
Harry GillisBerenberg